Novel	O
antibody	B:C0003241
probes	O
for	O
the	O
characterization	O
of	O
endosialin	B:C1437495
/	O
Tumor	B:C1437495
Endothelial	I:C1437495
Marker	I:C1437495
-	I:C1437495
1.	I:C1437495
Endosialin	B:C1437495
(	I:C1437495
Tumor	I:C1437495
Endothelial	I:C1437495
Marker	I:C1437495
-	I:C1437495
1	I:C1437495
(	I:C1437495
TEM	I:C1437495
-	I:C1437495
1	I:C1437495
)	I:C1437495
,	I:C1437495
CD248	I:C1437495
)	I:C1437495
is	O
primarily	O
expressed	O
on	O
pericytes	B:C0598800
of	O
tumor	B:C0027651
-	O
associated	O
microvasculature	B:C0243079
,	O
tumor	B:C0027651
-	O
associated	O
stromal	B:C0162597
cells	I:C0162597
and	O
directly	O
on	O
tumors	B:C0027651
of	O
mesenchymal	B:C1257975
origin	I:C1257975
,	O
including	O
sarcoma	B:C1261473
and	O
melanoma	B:C0025202
.	O

While	O
the	O
function	O
of	O
endosialin	B:C1437495
/	I:C1437495
TEM	I:C1437495
-	I:C1437495
1	I:C1437495
is	O
incompletely	O
understood	O
,	O
studies	B:C2603343
have	O
suggested	O
a	O
role	O
in	O
supporting	O
tumor	O
growth	O
and	O
invasion	B:C1269955
thus	O
making	O
it	O
an	O
attractive	O
therapeutic	O
target	O
.	O

In	O
an	O
effort	O
to	O
further	O
understand	O
its	O
role	O
in	O
cancer	B:C0006826
,	O
we	O
previously	O
developed	O
a	O
humanized	B:C2985546
anti-endosialin	B:C1437495
/	I:C1437495
TEM	I:C1437495
-	I:C1437495
1	I:C1437495
monoclonal	B:C0003250
antibody	I:C0003250
(	O
monoclonal	B:C0003250
antibody	I:C0003250
)	O
,	O
called	O
ontuxizumab	B:C2826153
(	O
MORAb	B:C2826153
-	I:C2826153
004	I:C2826153
)	O
for	O
testing	O
in	O
preclinical	B:C1709631
and	O
clinical	B:C0008972
studies	I:C0008972
.	O

We	O
herein	O
report	O
on	O
the	O
generation	O
of	O
an	O
extensive	O
panel	O
of	O
recombinant	B:C0034861
endosialin	B:C1437495
/	I:C1437495
TEM	I:C1437495
-	I:C1437495
1	I:C1437495
protein	I:C1437495
extracellular	B:C1517050
domain	I:C1517050
(	O
extracellular	B:C1517050
domain	I:C1517050
)	O
fragments	B:C0030935
and	O
novel	O
mAbs	B:C0003250
against	O
extracellular	B:C1517050
domain	I:C1517050
motifs	B:C1514562
.	O

The	O
domain	B:C1149343
-	I:C1149343
specific	I:C1149343
epitopes	B:C0003316
were	O
mapped	O
against	O
extracellular	B:C1517050
domain	I:C1517050
sub	O
-	O
domains	O
to	O
identify	O
those	O
that	O
can	O
detect	B:C0442726
distinct	O
structural	B:C0678594
motifs	B:C1514562
and	O
can	O
be	O
potentially	O
formatted	O
as	O
probes	O
suitable	O
for	O
diagnostic	B:C1704656
and	O
functional	O
studies	O
.	O

A	O
number	O
of	O
mAbS	B:C0003250
were	O
shown	O
to	O
cross-react	B:C0541850
with	O
the	O
murine	B:C0591833
and	O
human	B:C0086418
protein	B:C0033684
,	O
potentially	O
allowing	O
their	O
use	O
in	O
human	B:C0086418
animal	B:C0599779
models	I:C0599779
and	O
corresponding	O
clinical	B:C0008976
trials	I:C0008976
.	O

In	O
addition	O
,	O
pairing	O
of	O
several	O
mAbs	B:C0003250
supported	O
their	O
use	O
in	O
immunoassays	B:C0523404
that	O
can	O
detect	O
soluble	B:C1749467
endosialin	B:C1437495
/	I:C1437495
TEM	I:C1437495
-	I:C1437495
1	I:C1437495
(	O
soluble	B:C1437495
endosialin	I:C1437495
/	I:C1437495
TEM	I:C1437495
-	I:C1437495
1	I:C1437495
)	O
in	O
the	O
serum	B:C0229671
of	O
healthy	B:C1708335
subjects	I:C1708335
and	O
cancer	O
patients	O
.	O

